These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29029010)

  • 1. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
    Chamilos G; Lionakis MS; Kontoyiannis DP
    Clin Infect Dis; 2018 Jan; 66(1):140-148. PubMed ID: 29029010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
    Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
    Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
    Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
    Egger M; Gornicec M; Wölfler A; Lembeck AL; Tinchon C; Maderdonner M; Prattes J
    Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36029283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Swan CD; Gottlieb T
    BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30021735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.
    Zarakas MA; Desai JV; Chamilos G; Lionakis MS
    Curr Fungal Infect Rep; 2019 Sep; 13(3):86-98. PubMed ID: 31555394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
    Cheng MP; Kusztos AE; Gustine JN; Dryden-Peterson SL; Dubeau TE; Woolley AE; Hammond SP; Baden LR; Treon SP; Castillo JJ; Issa NC
    Br J Haematol; 2019 May; 185(4):788-790. PubMed ID: 30460682
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of Major Bleeding with Ibrutinib.
    Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
    Reinwald M; Silva JT; Mueller NJ; Fortún J; Garzoni C; de Fijter JW; Fernández-Ruiz M; Grossi P; Aguado JM
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S53-S70. PubMed ID: 29454849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
    Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR
    Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 17. The Muddied Waters of Ibrutinib Therapy.
    Schamroth Pravda M; Schamroth Pravda N; Lishner M
    Acta Haematol; 2019; 141(4):209-213. PubMed ID: 30943468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
    Fabbro SK; Smith SM; Dubovsky JA; Gru AA; Jones JA
    JAMA Oncol; 2015 Aug; 1(5):684-6. PubMed ID: 26182170
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
    Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
    Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.